Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 20, 2022

Efficacy and Safety of Rezivertinib in Locally Advanced or Metastatic/Recurrent EGFR T790M–Mutated NSCLC

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic/recurrent EGFR T790M mutated NSCLC: a phase IIb study
J Thorac Oncol 2022 Aug 29;[EPub Ahead of Print], Y Shi, S Wu, K Wang, S Cang, W Yao, Y Fan, L Wu, M Huang, X Li, Y Pan, Z Yang, B Zhu, G Chen, J Shi, M Sun, J Fang, L Wang, Z Chen, C Liu, J Li, J Liu, S Sun, Y Zhao, Y Guo, Z Meng, Z Liu, Z Han, H Lu, R Ma, S Hu, G Zhao, Z Liu, C Xie, D Zhong, H Zhao, H Yu, L Zhang, M Bi, S Yi, S Guo, T Yi, W Li, Y Lin, Y Shu, Z Chen, Z Guo, M Greco, T Wang, H Shen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading